In collaboration with CiRA, Kyoto University, the National Institute of Health Sciences and with funding from NEDO, Takara is developing commercial mass production of myocardial cells generated from iPS cells, for use in the clinical testing of cardiac toxicity evaluation of drugs. The project is supported by NEDO with 200 million Yen.
NEDO news release, Oct. 30, 2014
Takara Bio will start mass production of cardiomyocytes from iPS cells by 2015